Coloplast delivered Q4 organic growth of 7% and an EBIT margin 1 of 28%. Reported revenue in DKK grew 0% with negative impact from currencies and the Skin Care divestment. • Organic growth rates by ...
Investing.com -- Coloplast delivered a solid fourth-quarter performance, with in-line organic sales growth (OSG) matching ...
Coloplast is now rated a cautious 'Buy,' as its valuation has become more reasonable after a significant price correction. Coloplast continues to deliver solid organic growth, boasts a wide economic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback